News for Verastem, Inc. (VSTM)

PR NewswireVANCOUVER, BC, March 8, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 8, 2025 /PRNewswire/

Nantahala Capital Management, LLC (Trades, Portfolio), a prominent investment firm, executed a significant stock transaction on December 31, 2024. The firm adde

On December 31, 2024, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio) executed a significant transaction by acquiring an additional 427,030 shares of Verastem

Significant Transaction by Alyeska Investment Group On December 31, 2024, Alyeska Investment Group, L.P. (Trades, Portfolio) executed a notable transaction invo

On December 31, 2024, Barclays PLC executed a significant transaction by acquiring 3,894,093 shares of Verastem Inc (VSTM) at a price of $5.17 per share. This s

Introduction to the Transaction On December 31, 2024, Balyasny Asset Management L.P. (Trades, Portfolio) executed a noteworthy transaction by acquiring 3,945,92

On December 31, 2024, Vanguard Group Inc. made a significant move by acquiring an additional 382,816 shares of Verastem Inc. at a price of $5.17 per share. This

Verastem Inc. (VSTM), doing business as Verastem Oncology, Wednesday announced the appointment of Matthew Ros as chief operating officer. Previously, Ros had served as chief executive officer and board director at FORE Biotherapeutics, an oncology company.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today ann

Verastem, Inc.'s promising therapy for LGSOC could position them as a commercial-stage company by 2025, capturing a big market share. Click for my VSTM update.

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ovarian carcinoma. Click to read.

Following news that the U.S. Food and Drug Administration approved its New Drug Application for avutometinib in combination with defactinib to treat recurrent l

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

U.K.-based Aptorum Group Limited (APM) is up over 329 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Verastem (VSTM) said the FDA has accepted for priority review its application for accelerated approval of its avutometinib/defactinib therapy for the treatment of ovarian cancer.

Verastem director Brian Stuglik sells $4,160 in stock

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem's promising progress in RAS-driven cancers, potential FDA approval, and growth opportunities present bullish outlook for investors. Click to read.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its managemen